181 related articles for article (PubMed ID: 7786592)
1. Long-term prognosis following macroscopic complete response at second-look laparotomy in advanced ovarian cancer patients treated with platinum-based chemotherapy. The Gruppo Oncologico Nord Ovest.
Chiara S; Lionetto R; Campora E; Oliva C; Merlini L; Bruzzi P; Rosso R; Conte PF
Eur J Cancer; 1995; 31A(3):296-301. PubMed ID: 7786592
[TBL] [Abstract][Full Text] [Related]
2. Surgical cytoreduction during second-look laparotomy in patients with advanced ovarian cancer.
Gadducci A; Iacconi P; Fanucchi A; Cosio S; Teti G; Genazzani AR
Anticancer Res; 2000; 20(3B):1959-64. PubMed ID: 10928134
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin-based combination chemotherapy with or without doxorubicin in advanced epithelial ovarian cancer: 8-year update of a randomized multicentric clinical trial. The Gruppo Oncologico Nord Ovest (GONO).
Gadducci A; Brunetti I; Bruzzone M; Carnino F; Chiara S; Conte PF; Fioretti P; Foglia G; Ragni N
Eur J Gynaecol Oncol; 1992; 13(1 Suppl):36-9. PubMed ID: 1511712
[TBL] [Abstract][Full Text] [Related]
4. Long-term results in patients with advanced epithelial ovarian carcinoma treated with a combination of cisplatin, doxorubicin, and cyclophosphamide.
Colozza M; Mosconi AM; Gori S; Belsanti V; Basurto C; De Angelis V; Giansanti M; Tonato M
Am J Clin Oncol; 1997 Oct; 20(5):522-6. PubMed ID: 9345342
[TBL] [Abstract][Full Text] [Related]
5. The prognostic and therapeutic value of second-look laparotomy in advanced ovarian cancer.
Bertelsen K; Hansen MK; Pedersen PH; Larsen G; Nyland M; Jacobsen M; Andersen JE
Br J Obstet Gynaecol; 1988 Dec; 95(12):1231-6. PubMed ID: 3224088
[TBL] [Abstract][Full Text] [Related]
6. Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest.
Gadducci A; Carnino F; Chiara S; Brunetti I; Tanganelli L; Romanini A; Bruzzone M; Conte PF
Gynecol Oncol; 2000 Feb; 76(2):157-62. PubMed ID: 10637064
[TBL] [Abstract][Full Text] [Related]
7. High-dose melphalan-based chemotherapy and autologous stem cell transplantation after second look laparotomy in patients with chemosensitive advanced ovarian carcinoma: long-term results.
Bertucci F; Viens P; Delpero JR; Bardou VJ; Faucher C; Houvenaeghel G; Maraninchi D
Bone Marrow Transplant; 2000 Jul; 26(1):61-7. PubMed ID: 10918406
[TBL] [Abstract][Full Text] [Related]
8. Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration.
Hainsworth JD; Grosh WW; Burnett LS; Jones HW; Wolff SN; Greco FA
Ann Intern Med; 1988 Feb; 108(2):165-70. PubMed ID: 3124679
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
Thigpen T; Vance R; Puneky L; Khansur T
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
[TBL] [Abstract][Full Text] [Related]
10. Intravenous chemotherapy, early debulking surgery, and consolidation intraperitoneal chemotherapy in advanced ovarian carcinoma.
Tournigand C; Louvet C; Molitor JL; Dehni N; Lejeune V; Sezeur A; Pigne A; Marpeau L; Cady J; de Gramont A
Gynecol Oncol; 2001 Nov; 83(2):198-204. PubMed ID: 11606072
[TBL] [Abstract][Full Text] [Related]
11. Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma.
Louie KG; Ozols RF; Myers CE; Ostchega Y; Jenkins J; Howser D; Young RC
J Clin Oncol; 1986 Nov; 4(11):1579-85. PubMed ID: 3095501
[TBL] [Abstract][Full Text] [Related]
12. Survival of women with advanced ovarian cancer and complete pathologic response at second-look laparotomy.
Bolis G; Villa A; Guarnerio P; Ferraris C; Gavoni N; Giardina G; Melpignano M; Scarfone G; Zanaboni F; Parazzini F
Cancer; 1996 Jan; 77(1):128-31. PubMed ID: 8630918
[TBL] [Abstract][Full Text] [Related]
13. A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA).
Bertelsen K; Jakobsen A; Strøyer J; Nielsen K; Sandberg E; Andersen JE; Ahrons S; Nyland M; Hjortkjaer Pedersen P; Larsen G
Gynecol Oncol; 1993 Apr; 49(1):30-6. PubMed ID: 8482557
[TBL] [Abstract][Full Text] [Related]
14. Long-term survival in advanced ovarian cancer after cytoreduction and chemotherapy treatment.
Del Campo JM; Felip E; Rubio D; Vidal R; Bermejo B; Colomer R; Zanon V
Gynecol Oncol; 1994 Apr; 53(1):27-32. PubMed ID: 8175018
[TBL] [Abstract][Full Text] [Related]
15. Long-term survival with consolidation intraperitoneal chemotherapy for patients with advanced ovarian cancer with pathological complete remission.
Tournigand C; Louvet C; Molitor JL; Fritel X; Dehni N; Sezeur A; Pigné A; Cady J; Milliez J; de Gramont A
Gynecol Oncol; 2003 Nov; 91(2):341-5. PubMed ID: 14599864
[TBL] [Abstract][Full Text] [Related]
16. Long-term survival of 106 stage III ovarian cancer patients with minimal residual disease after second-look laparotomy and consolidation radiotherapy.
Petit T; Velten M; d'Hombres A; Marchal C; Montbarbon X; Mornex F; Quetin P; Gérard JP; Romestaing P; Carrie C
Gynecol Oncol; 2007 Jan; 104(1):104-8. PubMed ID: 16987544
[TBL] [Abstract][Full Text] [Related]
17. The role of second-look laparotomy in the management of patients with stage II, III and IV ovarian cancers following chemotherapy with cisplatin, adriamycin and cyclophosphamide.
Kirwan PH; Naftalin NJ; Khanna S; Aukett RJ
Br J Obstet Gynaecol; 1986 Jun; 93(6):629-33. PubMed ID: 3730331
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors for recurrence following negative second-look laparotomy in ovarian cancer patients treated with platinum-based chemotherapy.
Rubin SC; Hoskins WJ; Saigo PE; Chapman D; Hakes TB; Markman M; Reichman B; Almadrones L; Lewis JL
Gynecol Oncol; 1991 Aug; 42(2):137-41. PubMed ID: 1894172
[TBL] [Abstract][Full Text] [Related]
19. Abdominopelvic irradiation for stage II-IV ovarian carcinoma patients with limited or no residual disease at second-look laparotomy after completion of cisplatinum-based combination chemotherapy.
Menczer J; Modan M; Brenner J; Ben-Baruch G; Brenner H
Gynecol Oncol; 1986 Jun; 24(2):149-54. PubMed ID: 3710262
[TBL] [Abstract][Full Text] [Related]
20. Long term survival by cytoreductive surgery to less than 1 cm, induction weekly cisplatin and monthly cisplatin, doxorubicin, and cyclophosphamide therapy in advanced ovarian adenocarcinoma.
Baker TR; Piver MS; Hempling RE
Cancer; 1994 Jul; 74(2):656-63. PubMed ID: 8033045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
